Premium
Leishmania tarentolae expressing CXCL ‐10 as an efficient immunotherapy approach against Leishmania major ‐infected BALB /c mice
Author(s) -
MontakhabYeganeh H.,
Abdossamadi Z.,
Zahedifard F.,
Taslimi Y.,
Badirzadeh A.,
Saljoughian N.,
Taheri T.,
Taghikhani M.,
Rafati S.
Publication year - 2017
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12461
Subject(s) - arginase , leishmania , biology , immunotherapy , leishmaniasis , immunology , leishmania major , chemokine , interleukin 10 , cytokine , nitric oxide , interferon gamma , potency , cutaneous leishmaniasis , recombinant dna , immune system , parasite hosting , arginine , in vitro , gene , biochemistry , amino acid , world wide web , computer science , endocrinology
Summary Recent findings have demonstrated the suitability of interferon‐gamma‐induced protein 10 ( IP ‐10) or CXCL ‐10 as an immunotherapy tool in treatment of leishmaniasis. This chemokine can overcome Leishmania ( L .) infection through inducing nitric oxide (NO) production for parasite elimination. This study was undertaken to investigate the therapeutic effects of recombinant Leishmania tarentolae expressing CXCL ‐10 and an expression vector encoding CXCL ‐10 (pc DNA ‐ CXCL ‐10‐ EGFP ) in a model of BALB /c mice susceptible to infection by Leishmania major . The outcome of intervention was examined at 3 weeks post‐treatment by evaluating the parameters of parasite burden (PB), arginase activity, NO and various cytokines such as IFN ‐γ, IL ‐4, IL ‐6 and IL ‐10. The results have shown that despite the efficacy of CXCL ‐10 expression vector as gene therapy, the live therapy strategy using L . tarentolae expressing CXCL ‐10 was more effective in terms of decreasing PB. Nitric oxide production increased, especially in the live therapy approaches. Arginase activity also decreased in all regimens, which demonstrates the potency of the treatment. The overall cytokine production shifted in favour of Th1 responses in the treated mice. Altogether, recombinant L. tarentolae expressing CXCL ‐10 represents a promising therapeutic strategy to improve treatment of cutaneous leishmaniasis.